Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 19/20 | 0.49 |
| ▸ | F3 | P13726 | 18/20 | 0.49 |
| ▸ | F2 | P00734 | 7/20 | 0.45 |
| ▸ | F10 | P00742 | 7/20 | 0.45 |
| ▸ | F11 | P03951 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7443963 | 0.94 | F7 (0.49) | F7F3F2F10F11 | |
| SCHEMBL3856774 | 0.91 | F7 (0.52) | F7F3F2F10F11 | |
| SCHEMBL5133553 | 0.85 | F7 (0.44) | F7F3F2F10F11 | |
| SCHEMBL3853926 | 0.85 | F7 (0.56) | F7F3F2F10F11 | |
| SCHEMBL3853924 | 0.84 | F7 (0.53) | F7F3F2F10F11 | |
| SCHEMBL3853921 | 0.84 | F7 (0.53) | F7F3F2F10F11 | |
| SCHEMBL5037211 | 0.83 | F7 (0.66) | F7F3F2F10F11 | |
| SCHEMBL3463923 | 0.83 | F7 (0.69) | F7F3F2F10F11 | |
| SCHEMBL5882260 | 0.83 | F7 (0.58) | F7F3F2F10F11 | |
| SCHEMBL2538383 | 0.82 | LMNA (0.40) | F7F3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1856096-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | Bristol-Myers Squibb Company (US) | 2007-11-21 | — | — | EP | disclosed |
| US-7250447-B2 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. (US) | 2007-07-31 | — | — | US | disclosed |
| US-20070037813-A1 | Serine Protease Inhibitors | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | GENENTECH, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY | 2006-07-27 | — | — | US | disclosed |
| WO-2006076246-A2 | PHENYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1628954-A2 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIA | Genentech, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| EP-1144373-B1 | SERINE PROTEASE INHIBITORS | GENENTECH INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050186198-A1 | Serine protease inhibitors | GENENTECH, INC. | 2005-08-25 | — | — | US | disclosed |
| US-6919369-B2 | Controlling blood coagulation | GENENTECH, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| WO-2004113278-A2 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIA | GENENTECH, INC. (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040242585-A1 | Acylsulfamide inhibitors of factor VIIa | GENENTECH, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20030212071-A1 | Serine protease inhibitors | GENENTECH, INC. | 2003-11-13 | — | — | US | disclosed |
| US-6472393-B1 | Serine protease inhibitors | GENENTECH, INC. | 2002-10-29 | — | — | US | disclosed |
| EP-1144373-A3 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1144373-A2 | SERINE PROTEASE INHIBITORS | Genentech, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000041531-A2 | SERINE PROTEASE INHIBITORS | GENENTECH, INC. (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212071-A1 | Serine protease inhibitors | SERPINE1, SPINT2, TFPI | F7 22/4885F3 45/4885F2 12/4885 |
| US-20070037813-A1 | Serine Protease Inhibitors | TFPI, SPINT2, SERPINE1 | F7 17/4885F3 43/4885F2 10/4885 |
| US-20050186198-A1 | Serine protease inhibitors | TFPI, SPINT2, SERPINE1 | F7 17/4885F3 43/4885F2 10/4885 |
| US-20070037814-A1 | ACYLSULFAMIDE INHIBITORS OF FACTOR VIIa | TFPI, HABP2, TFPI2 | F7 4/4885F3 41/4885F2 28/4885 |
| US-20060166997-A1 | Phenylglycinamide derivatives useful as anticoagulants | TFPI, SERPINC1, SERPINE1 | F7 35/4885F3 20/4885F2 9/4885 |
| US-20040242585-A1 | Acylsulfamide inhibitors of factor VIIa | TFPI, TFPI2, HABP2 | F7 6/4885F3 46/4885F2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.